趋化因子CXCL16和CA153及TSGF在乳腺癌诊断中的应用
|
摘要
目的探讨趋化因子C-X-C-基元配体16(CXCL16)、乳腺癌相关抗原(CA153)和恶性肿瘤特异生长因子(TSGF在乳腺癌诊断和治疗监测中的应用。方法采用酶联免疫吸附试验(ELISA)检测2015年1月1日至2017年12月31日收治的50例健康女性体检者(健康对照组)、72例良性乳腺肿瘤患者(良性乳腺疾病组)、94例乳腺癌患者(乳腺癌组)和83例其他肿瘤患者(其他肿瘤组)外周血中CXCL16,酶法检测TSGF,化学发光法检测CA153,并进行对比分析。结果乳腺癌组的3种指标均高于健康对照组和良性乳腺疾病组,乳腺癌组的CA153水平高于其他肿瘤组,差异均有统计学意义(P<0.05)。而乳腺癌组及其他肿瘤组CXCL16、TSGF水平比较,差异均无统计学意义(P>0.05)。在乳腺癌组中,随着临床分期的升高,CXCL16、CA153和TSGF水平递增,Ⅲ+Ⅳ期显著高于Ⅰ+Ⅱ期,有淋巴结转移者显著高于无转移者,差异均有统计学意义(P<0.05)。与手术前比较,乳腺癌组81例患者CXCL16、CA153和TSGF水平在手术后显著下降,差异均有统计学意义(P<0.05)。CA153特异性最高,CXCL16灵敏度最高,CXCL16、CA153和TSGF联合检测可提高对乳腺癌灵敏度、阴性预测值和阳性预测值。结论CXCL16、CA153和TSGF对乳腺癌术后随访有一定的意义,CXCL16、CA153和TSGF联合检测有助于提高对乳腺癌的早期诊断率。
Objective To discuss clinical application of CXCL16 and CA153 and TSGF in the diagnosis and therapy of breast cancer.Methods CXCL16 in 50 health women(healthy control group),72 patients with benign breast disease(benign breast disease group)and 94 patients with malign breast disease(breast cancer group)and 83 patients with other malignant tumors(other tumor group)of the hospital from January 1,2015 to December 31,2017 were detected by ELSIA.TSGF were detected by enzyme method.CA153 was detected by chemical luminous method.The results were analyzed comparatively.Results CXCL16 and CA153 and TSGF in breast cancer group were higher than those in healthy controls group and benign breast disease group,CA153 in breast cancer group were higher than those in other tumor group,the differences were statistically significant(P<0.05).There were no significant differences in CXCL16 and TSGF between breast cancer group and other tumor group(P>0.05).In breast cancer group,with the increase of clinical stages,and CXCL16 and CA153 and TSGF in the stage ofⅢ+Ⅳ were higher than those ofⅠ+Ⅱ,the lymph node metastasis was significantly higher than that in the non metastasis,the differences were statistically significant(P<0.05).Compared with that before surgery,the levels of CXCL16,CA153,and TSGF in 81 patients in the breast cancer group decreased significantly after surgery,with statistically significant differences(P<0.05).The specificity of CA153 was highest.The sensitivity of CXCL16 was highest.The sensitivity and negative predictive and positive predictive value were improved by the combined of CA153 and CXCL16 and TSGF.Conclusion CXCL16 and CA153 and TSGF can follow-up the curative effect of breast cancer after operation,the joint detection of CXCL16、CA153 and TSGF is helpful to improve the rate of early diagnosis of breast cancer.
Objective To discuss clinical application of CXCL16 and CA153 and TSGF in the diagnosis and therapy of breast cancer.Methods CXCL16 in 50 health women(healthy control group),72 patients with benign breast disease(benign breast disease group)and 94 patients with malign breast disease(breast cancer group)and 83 patients with other malignant tumors(other tumor group)of the hospital from January 1,2015 to December 31,2017 were detected by ELSIA.TSGF were detected by enzyme method.CA153 was detected by chemical luminous method.The results were analyzed comparatively.Results CXCL16 and CA153 and TSGF in breast cancer group were higher than those in healthy controls group and benign breast disease group,CA153 in breast cancer group were higher than those in other tumor group,the differences were statistically significant(P<0.05).There were no significant differences in CXCL16 and TSGF between breast cancer group and other tumor group(P>0.05).In breast cancer group,with the increase of clinical stages,and CXCL16 and CA153 and TSGF in the stage ofⅢ+Ⅳ were higher than those ofⅠ+Ⅱ,the lymph node metastasis was significantly higher than that in the non metastasis,the differences were statistically significant(P<0.05).Compared with that before surgery,the levels of CXCL16,CA153,and TSGF in 81 patients in the breast cancer group decreased significantly after surgery,with statistically significant differences(P<0.05).The specificity of CA153 was highest.The sensitivity of CXCL16 was highest.The sensitivity and negative predictive and positive predictive value were improved by the combined of CA153 and CXCL16 and TSGF.Conclusion CXCL16 and CA153 and TSGF can follow-up the curative effect of breast cancer after operation,the joint detection of CXCL16、CA153 and TSGF is helpful to improve the rate of early diagnosis of breast cancer.
引文
[1]付维书,刘艳霞,袁洪霞,等.肿瘤标志物联合检测在乳腺癌诊断中的临床意义[J].国际检验医学杂志,2015,36(19):2902-2903.
[2]孙昌瑞,邓君,冯林,等.乳腺癌患者外周血循环肿瘤细胞分子学检测方法的对比研究[J].中华检验医学杂志,2015,38(10):666-671.
[3]王延博,林玲,李宇球,等.SDF-1,CXCL16水平在包含HFmrEF组的慢性心力衰竭患者中的变化[J].临床心血管病杂志,2018,34(3):249-254.
[4]周雯慧,刘越,胡卫东,等.趋化因子及其受体CXCL16/CX-CR6在人肺癌转移中的作用[J].中华微生物学和免疫学杂志,2011,31(12):1076-1080.
[5]谢莉莉,王东林.乳腺癌患者HER-2、PCNA和E-cadherin蛋白表达及临床病理特征与预后的相关性[J].现代肿瘤医学,2017,25(18):2929-2934.
[6]汤红平,刘芳,陈国艳,等.趋化因子CXCL16在乳腺癌中的表达及其意义[J].中华乳腺病杂志:电子版,2014,8(6):13-16.
[7]程浩,陈念永.趋化因子受体CXCR6在乳腺癌细胞系中的表达及其意义[J].四川大学学报(医学版),2014,45(3):405-409.
[8] XING YN,ZHANG JY,XU HM.The roles of serum c Xcl16in circulating Tregs and gastrointestinal stromal tumor cells[J].Onco Targets Ther,2016,9:3939-3949.
[9] SLATER EP,FENDRICH V,STAUCH K,et al.LCN2and TIMP1as potential serum markers for the early detection of familial pancreatic cancer[J].Transl Oncol,2013,6(2):99-103.
[10]李宏杰,胡新荣,袁利.血清肿瘤标志物CA153、CA125、HER-2检测在乳腺癌诊断中的价值[J].河南外科学杂志,2018,24(1):32-33.
[11]迪力夏提·金斯汗,吐鲁洪·沙列尔,赵倩.联合检测血清Hcy,CA15-3和FA对乳腺癌的临床价值分析[J].临床肿瘤学杂志,2017,21(6):500-503.
[12]贾举闻,付峥,葛麟,等.血清半乳凝素-3,糖类抗原153和肿瘤特异生长因子结合乳腺钼靶X线对乳腺癌的早期诊断价值[J].中国肿瘤临床与康复,2017,24(2):135-138.
[2]孙昌瑞,邓君,冯林,等.乳腺癌患者外周血循环肿瘤细胞分子学检测方法的对比研究[J].中华检验医学杂志,2015,38(10):666-671.
[3]王延博,林玲,李宇球,等.SDF-1,CXCL16水平在包含HFmrEF组的慢性心力衰竭患者中的变化[J].临床心血管病杂志,2018,34(3):249-254.
[4]周雯慧,刘越,胡卫东,等.趋化因子及其受体CXCL16/CX-CR6在人肺癌转移中的作用[J].中华微生物学和免疫学杂志,2011,31(12):1076-1080.
[5]谢莉莉,王东林.乳腺癌患者HER-2、PCNA和E-cadherin蛋白表达及临床病理特征与预后的相关性[J].现代肿瘤医学,2017,25(18):2929-2934.
[6]汤红平,刘芳,陈国艳,等.趋化因子CXCL16在乳腺癌中的表达及其意义[J].中华乳腺病杂志:电子版,2014,8(6):13-16.
[7]程浩,陈念永.趋化因子受体CXCR6在乳腺癌细胞系中的表达及其意义[J].四川大学学报(医学版),2014,45(3):405-409.
[8] XING YN,ZHANG JY,XU HM.The roles of serum c Xcl16in circulating Tregs and gastrointestinal stromal tumor cells[J].Onco Targets Ther,2016,9:3939-3949.
[9] SLATER EP,FENDRICH V,STAUCH K,et al.LCN2and TIMP1as potential serum markers for the early detection of familial pancreatic cancer[J].Transl Oncol,2013,6(2):99-103.
[10]李宏杰,胡新荣,袁利.血清肿瘤标志物CA153、CA125、HER-2检测在乳腺癌诊断中的价值[J].河南外科学杂志,2018,24(1):32-33.
[11]迪力夏提·金斯汗,吐鲁洪·沙列尔,赵倩.联合检测血清Hcy,CA15-3和FA对乳腺癌的临床价值分析[J].临床肿瘤学杂志,2017,21(6):500-503.
[12]贾举闻,付峥,葛麟,等.血清半乳凝素-3,糖类抗原153和肿瘤特异生长因子结合乳腺钼靶X线对乳腺癌的早期诊断价值[J].中国肿瘤临床与康复,2017,24(2):135-138.